Structure of the Antimicrobial Peptide Tachystatin A*
Naoki
Fujitani
,
Shun-ichiro
Kawabata§¶
,
Tsukasa
Osaki§,
Yasuhiro
Kumaki
,
Makoto
Demura
,
Katsutoshi
Nitta
**, and
Keiichi
Kawano
From the
Division of Biological Sciences, Graduate
School of Science, Hokkaido University, Sapporo 060-0810, Japan, the
§ Department of Molecular Biology, Graduate School of
Medical Science, Kyushu University, Fukuoka 812-8582, Japan, the
¶ Department of Biology, Kyushu University, Fukuoka 812-8581, Japan, the 
Faculty of Pharmaceutical
Sciences, Toyama Medical and Pharmaceutical University, Toyama
930-0194, Japan, and
Core Research for Evolutional
Science and Technology (CREST), Japan Science and Technology Corp.,
Tokyo 101-0062, Japan
Received for publication, November 20, 2001, and in revised form, April 14, 2002
 |
ABSTRACT |
The solution structure of antimicrobial peptide
tachystatin A from the Japanese horseshoe crab (Tachypleus
tridentatus) was determined by two-dimensional nuclear magnetic
resonance measurements and distance-restrained simulated annealing
calculations. The correct pairs of disulfide bonds were also confirmed
in this study. The obtained structure has a cysteine-stabilized
triple-stranded
-sheet as a dominant secondary structure and shows
an amphiphilic folding observed in many membrane-interactive peptides.
Interestingly, tachystatin A shares structural similarities with the
calcium channel antagonist
-agatoxin IVA isolated from spider toxin
and mammalian defensins, and we predicted that
-agatoxin IVA also have the antifungal activity. These structural comparisons and functional correspondences suggest that tachystatin A and
-agatoxin IVA may exert the antimicrobial activity in a manner similar to defensins, and we have confirmed such activity using fungal culture assays. Furthermore, tachystatin A is a chitin-binding peptide, and
-agatoxin IVA also showed chitin-binding activities in this study.
Tachystatin A and
-agatoxin IVA showed no structural homology with
well known chitin-binding motifs, suggesting that their structures belong to a novel family of chitin-binding peptides. Comparison of
their structures with those of cellulose-binding proteins indicated that Phe9 of tachystatin A might be an essential residue
for binding to chitin.
 |
INTRODUCTION |
There is no acquired immunity in invertebrate animals, which lack
a system for the production of antibodies. Therefore, antimicrobial proteins, lectins, and phenoloxidases play the most important role in
the host-defense activities of invertebrates (1-3). Although vertebrate animals have acquired innate immunities and are defended by
their complex defense activities, invertebrate animals cannot use the
diversification of antibodies, and the defending molecules must
distinguish self from nonself. Self-defense by antimicrobial substances
involves a direct attack on infectious agents. This is the fundamental
mechanism of the host-defense systems identified in all species,
including both invertebrate and vertebrate animals, and is an important
object of study with regard to biological and immunological
self-defense reactions.
The defense actions of the horseshoe crab have been found to be carried
out by innate immune substances derived from hemocytes in hemolymph
plasma (2, 4-6). Whereas the hemolymph of crustacean animals in
general have three kinds of hemocytes (granular, small granular, and
nongranular), in the case of the horseshoe crab, granular hemocytes
comprise 99% of all hemocytes. The granular hemocytes contain two
kinds of granules, large and small, which store the peptides and
proteins related to self-defense activities (7). The clotting factors
are stored in the large granules, and most antimicrobial substances are
present in the small ones (7). The hemocytes are sensitive to
lipopolysaccharides, which are major components of the outer
membrane of Gram-negative bacteria, and defense molecules are secreted
by exocytosis to clot body fluid and to kill infectious pathogens in
response to lipopolysaccharide stimulation (2, 7-8). The following
four antimicrobial peptides have been characterized in the small
granules: tachyplesins (4), big defensin (5), tachycitin (6), and
tachystatins (9).
Tachystatin A consists of two isopeptides made up of 44 amino acid
residues; tachystatin A1 contains phenylalanine at the C-terminal end,
and tachystatin A2 contains tyrosine at the corresponding site (9).
Tachystatin A inhibits the growth of Gram-negative bacteria,
Gram-positive bacteria, and fungi (9). Whereas tachystatin A has no
similarities with the other three peptides in terms of molecular mass
or amino acid sequence, tachystatin A shows weak sequence similarity to
-agatoxin IVA (
-aga
IVA)1 (10), a P-type calcium
channel (11, 12) antagonist found in the venom of the funnel web spider
(Agelenopsis aperta). Because the horseshoe crab is an
invertebrate animal phylogenetically close to spiders and scorpions, it
is possible that both molecules have a common ancestor. Furthermore,
tachystatin A has a chitin-binding property that is a common feature of
the components of small granular derived antimicrobial peptides. It is
likely that this property has two explanations. First, the property may
be important for killing fungal pathogens, because chitin is one of the
major components of the fungal cell wall. Second, this property may
contribute to the healing of the damaged exoskeleton of the horseshoe
crab, since chitin is the major component of this exoskeleton.
In this study, we determined the structure of tachystatin A in an
aqueous solution using two-dimensional 1H NMR spectroscopy
and distance geometry-simulated annealing calculations. The solution
structure involved a triple-stranded
-sheet and two
-turns. This
folding differed from that of the antimicrobial peptides, tachyplesins
(13) and tachycitin (14), isolated from the horseshoe crab. With
respect to the chitin-binding property, no chitin-binding domains with
the structural motif of tachystatin A have yet been found. In this
paper, we show that the folding of tachystatin A produces a unique
motif not only as an antimicrobial peptide but also as a chitin-binding peptide.
 |
EXPERIMENTAL PROCEDURES |
NMR Spectroscopy--
Hemocyte debris from the Japanese
horseshoe crab (Tachypleus tridentatus) was prepared by the
methods of Nakamura et al. (4), and tachystatin A was
purified by the methods of Osaki et al. (9). Samples were
prepared for NMR spectroscopy by dissolving tachystatin A in 10%
D2O, 90% H2O or 99% D2O at
a final concentration of 2 mM. The sample pH was adjusted
to 3.5 to observe amide protons by decreasing the hydrogen-deuterium
exchange rates.
All NMR spectra were observed on a JEOL JNM-alpha 500 spectrometer
operating at a proton frequency of 500 MHz with a sample temperature of
298 K. Two-dimensional DQF-COSY (15), TOCSY with MLEV-17 spin lock
sequence (16, 17), NOESY (18), and E. COSY (19) measurements were
recorded in a phase-sensitive mode. TOCSY spectra were obtained with
mixing times of 80 and 100 ms. NOESY spectra were recorded with mixing
times of 100, 150, and 300 ms. For water signal suppression, the DANTE
pulse method (20) was applied to all NMR experiments. The proton
chemical shifts were referenced to external sodium 3-(trimethylsilyl)
propionate-2,2,3,3-D4. The spectral width of all
measurements was 6002.40 Hz. All two-dimensional measurements were
recorded with 1024 × 512 frequency data points and were
zero-filled to yield 1024 × 1024 data matrices except for the
high resolution DQF-COSY and E. COSY. High resolution DQF-COSY and E. COSY were recorded with 4096 × 512 data points in the
t2 and t1 dimensions,
respectively, and zero-filled to 8192 × 8192 points to measure
the coupling constants. All NMR data were processed by NMRPipe software
(21). Time domain data in both dimensions were multiplied by a sine
bell window function with a 90° phase shift prior to Fourier
transformation. Base-line correction was applied using a fifth order polynomial.
All NMR spectra were assigned with the program XEASY (22). DQF-COSY and
TOCSY spectra recorded with the samples dissolved in H2O
were used to identify the spin systems of all residues. In addition,
one-dimensional and DQF-COSY spectra were used to identify the amide
protons protected from solvent exchange using a sample that had been
lyophilized from H2O solution and resuspended in
D2O.
Structure Calculations--
Three-dimensional structures of
tachystatin A were calculated with the program X-PLOR 3.1 (23) on the
R5000 processors of a Silicon Graphics Indy work station.
Distance restraints for calculations were estimated from the cross-peak
intensities in NOESY spectra with a mixing time of 150 ms; the
estimated restraints were then classified as strong, medium, or weak
and assigned upper limits of 2.7, 3.5, and 5.0 Å, respectively.
Pseudo-atom corrections were used for unresolved NOE cross-peaks and
those of methyl protons, nonstereospecifically assigned methylene, and
aromatic protons according to the protocol of X-PLOR. In addition, 0.5 Å was added to the upper limit of the distance constraints of only the
involved methyl protons according to the report by Clore et
al. (24). The restraints of the dihedral angle
were based on
3JHN
coupling constants measured
in high resolution DQF-COSY and E-COSY. When
3JHN
was more than 8.0 Hz, the
dihedral angle
was constricted to
120 ± 40°. Hydrogen
bond restraints were used as distance constraints of 1.5-2.5 Å between amide protons and carbonyl oxygens and 2.5-3.5 Å between
amide nitrogens and amide protons. All analyses of r.m.s. of difference
values as well as secondary and tertiary structures of tachystatin A
were performed with the program MOLMOL (25).
Determination of Disulfide Linkages--
Tachystatin A was
dissolved in 0.1 M Tris-HCl, pH 6.8, containing 2 M urea, and digested with trypsin and thermolysin
(E/S ratio = 1:20, w/w) at 37 °C for 16 h. The
digest was separated by reverse-phase high pressure liquid
chromatography on a Chemcosorb 5-ODS-H column (2.1 × 150 mm;
Chemco Scientific Co., Ltd., Osaka, Japan). Peptides containing
disulfide bonds were identified by amino acid analysis after performic
acid oxidation.
Antimicrobial Activity and Chitin-binding Assay for
-aga
IVA--
Antimicrobial activity of
-agatoxin IVA was assayed as
described by Saito et al. (5). Pichia pastoris
was plated on nutrient agar plates. Fungal culture was collected at the
logarithmic phase of growth, washed twice with 10 mM
phosphate buffer (pH 7.0), and adjusted to 5000-10000 cells/ml with
the same buffer. The peptide solution (50 µl) was added to 450 µl
of the fungal suspension, and the mixture was incubated at 30 °C for
1 h. An aliquot of the reaction mixture (100 µl) was then plated
onto the agar plate. After 24 h of incubation at 30 °C, the
number of colonies on the plates was counted. As a control experiment,
the phosphate buffer was added to the fungal suspension, and the
mixture was incubated for 1 h, plated on agar, and cultured.
Chitin (0.5 mg) was mixed with
-aga IVA in 100 µl of 20 mM Tris-HCl buffer (pH 7.5) containing 0.15 M
NaCl and 2 mM CaCl2 and then incubated at room
temperature for 15 min and centrifuged at 15,000 rpm for 2 min. The
supernatant was removed, and the precipitate was washed with 1 ml of
the same buffer and then eluted with 100 µl of 0.1 M HCl.
The peptide concentrations of the eluate were determined using a micro
BCATM protein assay kit from Pierce.
 |
RESULTS |
Identifications of Secondary Structures--
Well resolved spectra
were obtained for the sample conditions and methods described under
"Experimental Procedures," and the cross-peaks observed in all of
the two-dimensional 1H NMR spectra were assigned
completely. Fig. 1 summarizes the sequential assignments derived from NOESY with a mixing time of 150 ms.
The sequential NOE connectivities deduced from the combination of
overall strong d
N(i, i + 1) and weak dNN(i, i + 1) indicate that the peptide is rich in
-structures (26). Medium and
long range NOEs were also assigned completely using NOESY spectra, and
no characteristic NOEs for the helical structure were found as a result
of the sequential assignments.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 1.
Summary of sequential NOE connectivities,
coupling constant 3JHN , and the slowly
exchanging backbone amino acid amide protons observed in tachystatin
A. The sequential NOEs, d N,
dNN, and d N, are indicated by
bars, and their intensities are classified as strong,
medium, or weak according to the heights of the
bars. 3JHN values of more than 8 Hz are indicated by upward arrows. Slowly
hydrogen-deuterium-exchanging amides are indicated by filled
circles. These were still observed in a DQF-COSY spectrum
recorded 24 h after dissolving in D2O.
|
|
The analysis of the one-dimensional spectra and DQF-COSY, which were
recorded 24 h after dissolving the sample in D2O,
revealed the backbone amide protons of Phe9,
Cys11, Leu27, Thr28,
Arg30, Gly39, Arg40,
Cys41, and Gln42 exchange slowly with a
deuterium solvent, thus indicating that these amide protons form
hydrogen bonds or are buried inside the molecule. The coupling
constants between
H and backbone NH,
3JHN
, the value of which is used to
determine the restraint of dihedral angle
, were estimated from the
high resolution DQF-COSY spectrum. Generally, residues consisting of a
-sheet produce a value of more than 8.0 Hz for
3JHN
, and those consisting of an
-helix
produce a value of less than 6.0 Hz (26). Coupling constants
3JHN
of more than 8.0 Hz were identified for
17 of the 44 residues in tachystatin A, and there were no peaks with a
3JHN
value of less than 6.0 Hz. Slowly
exchanging amides and coupling constants
3JHN
are also summarized in Fig. 1. The
above evidence regarding 3JHN
and exchange
rates as well as the properties of sequential assignments may suggest
that tachystatin A is rich in
-structures.
It was possible to identify the secondary structure of tachystatin A as
consisting of a triple-stranded antiparallel
-sheet constructed by
Phe9-Val12,
Thr28-Arg30, and
Gly39-Gln42 from the compatible combination of
NOEs,
angle values estimated from 3JHN
,
and hydrogen bonds predicted by slowly exchanging amide protons. As an
important factor in the determination of the
-sheet, three long
range NOEs were observed between
Hs, which are located between
Asn10 and Arg40, Val12 and
Tyr38, and Cys29 and Cys41. Fig.
2 shows a schematic diagram of this
-sheet structure, including the observed NOEs and hydrogen bonds.
From these analyses, it was found that the main element of the
secondary structure of tachystatin A is a triple-stranded
-sheet
with a topology of +2x,
1 (27).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
The -sheet schematic
diagram in tachystatin A. Observed NOEs are shown by
arrows, and slowly exchanging protons are
circled. Dashed lines show the
predicted hydrogen bonds. Two tight turns are also identified by NOE
networks.
|
|
Determination of Disulfide Bonds and Global
Structure--
Tachystatin A was treated with iodoacetamide in the
presence of 8 M urea, under nonreducing conditions. Amino
acid analysis revealed that no cysteine residues were
S-alkylated, thereby indicating the presence of three
disulfide bonds. The intact tachystatin A was digested with trypsin and
thermolysin, and one disulfide-containing peptide (T-TL-15) was
isolated, as described under "Experimental Procedures." By amino
acid analysis, T-TL-15 was found to be composed of two chains,
Phe9-Cys11 and
Leu27-Arg30, indicating the presence of a
disulfide linkage of Cys11-Cys29. Peptides
containing the remaining two disulfide bonds could not be isolated,
because the -Cys23-Cys24- sequence was highly
resistant to proteolytic digestion. These disulfide bonds connecting
Cys23, Cys24, and the remaining two cysteine
residues have been established by nuclear magnetic resonance, which we
used to elucidate the conformational structure of tachystatin A.
We carried out the structural calculations using the program X-PLOR
version 3.1 (23) to determine the three-dimensional solution structure
of tachystatin A with the restraints derived from NMR experiments. This
solution structure consisted of 274 intramolecular NOEs, 19 dihedral
angles, and 22 hydrogen bonds. The 274 NOEs as distance restraints
included 56 intraresidues (|i
j|= 0), 120 sequential
(|i
j|= 1), 20 medium range (2
|i
j|
4), and 78 long range
(|i
j|
5) NOEs.
In the first step, the structure calculations were performed without
the restraints of dihedral angles, hydrogen bonds, or disulfide bonds
and with only the distance constraints estimated from the NOE
intensity. Restraints with large violations were removed or modified in
this step. In the next step, a total of 22 hydrogen bond and three
disulfide bond restraints were added for calculation. Hydrogen bond
restraints were added for the pairs indicated in the analysis of
secondary structure shown in Fig. 2. Although three pairs of disulfide
bonds are composed of six cysteines, positions 4, 11, 23, 24, 29, and
41 in this molecule, only one pair,
Cys11-Cys29, was determined by chemical
methods. There are three possibilities in the other two pairs,
Cys4-Cys23 and
Cys24-Cys41,
Cys4-Cys24 and
Cys23-Cys41, and
Cys4-Cys41 and
Cys23-Cys24. In the NOESY spectra, the NOE
cross-peaks that correspond to disulfide bonds were observed between
the
protons of Cys4 and Cys24 and of
Cys23 and Cys41. However, no NOE cross-peaks
corresponding to the other patterns of disulfides were observed. These
results strongly suggested that the reasonable disulfide bonds are
Cys4-Cys24 and
Cys23-Cys41.
In addition, to confirm the correct connections from the standpoint of
energetic study, the calculations were performed with Cys11-Cys29 connectivity and with one of three
patterns of disulfide bond connectivities,
Cys4-Cys23 and
Cys24-Cys41,
Cys4-Cys24 and
Cys23-Cys41, or
Cys4-Cys41 and
Cys23-Cys24. Well converged structures were
then obtained in the case of Cys4-Cys24 and
Cys23-Cys41 at 110 kcal/mol and 80 kcal/mol
lower than the structures obtained with disulfide bonds
Cys4-Cys23 and
Cys24-Cys41 and
Cys4-Cys41 and
Cys23-Cys24, respectively, in terms of the
average total molecular potential energy calculated by X-PLOR. The
energy analysis of these sets of structures proved that the disulfide
bonds Cys4-Cys24 and
Cys23-Cys41 were the correct bonds, so these
pairs were used for the final calculation step.
Finally, a family of 20 accepted three-dimensional structures was
selected with the lowest potential energies that contained no
experimental violations greater than 1.0 Å and 1° in the distance and torsion angle restraints, respectively. In a Ramachandran plot,
99.6% of the backbone dihedral angles of the 20 converged structures
fall either in the
-sheet region or in generally allowed regions. A
summary of the energetic statistics for tachystatin A is shown in Table
I. Pairwise r.m.s. of difference values
for the 20 lowest energy structures of well defined regions of the 4-14, 21-32, and 37-42 residues were found to be 0.70 Å for
backbone atoms and 1.63 Å for all heavy atoms when the structures were fitted in this region.
View this table:
[in this window]
[in a new window]
|
Table I
Structural statistics for 20 structures of tachystatin A
All energies and r.m.s. of difference values were calculated using the
programs X-PLOR 3.1 (23) and MOLMOL, respectively (25).
|
|
Fig. 3 represents the superposition of
the backbone coordinates for 20 converged structures. The topology and
constituting residues of the
-sheet determined by calculations were
found to correspond to those determined by the analysis of secondary structures mentioned above. Two tight turns,
Leu6-Phe9 and
Cys24-Leu27, were also identified in the
peptide using the standard criterion that the distance between
C(i) and
C(i + 3) is less than 7 Å (28)
and with the characteristic NOE connectivities. The distances between
C atoms at positions i and i + 3 of the first
(Leu6-Phe9) and second
(Cys24-Leu27)
-turns were 5.16 and 5.39 Å,
respectively. Although the first turn had a nearly type II conformation
from the viewpoint of the dihedral angles of constructing residues,
there was no capability to form an intraturn hydrogen bond, because
Phe9 was involved in the first strand, and the carbonyl
formed a hydrogen bond with the amide of Cys41. This turn
was therefore defined as a
E
-type turn (29) (i.e. a type IV turn (miscellaneous type) in the
classical nomenclature). In contrast, the second turn has a typical
type II (
P
-type) conformation with an intraturn
hydrogen bond between Cys24 and Leu27.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3.
The NMR structure of tachystatin A. A, superposition of the backbones of all 20 tachystatin A
conformers. B, ribbon representation of the lowest energy
model of tachystatin A. These images were generated by the
program MOLMOL (25).
|
|
The loop regions with disordered conformation were constructed by
Tyr16-Pro22 (loop 1) and
Tyr32-Thr37 (loop 2). The average r.m.s. of
difference values for these loops were 2.57 and 1.63 Å for the
backbone atoms, respectively, when the structures were superposed as
shown in Fig. 3. Both loops were rich in hydrophobic residues, and most
of these residues were exposed to solvent. Because the hydrophobicity
encourages interaction with the membrane, these loops might be an
important factor in interactions with the bacterial membrane.
Comparison with the Ca2+ Channel Blocker and
Evolutionary Considerations--
Whereas few structural similarities
have been identified between tachystatin A and other invertebrate
antimicrobial peptides, it has been found that tachystatin A shows a
weak amino acid sequence homology (22%) with
-aga IVA (10), a
P-type calcium channel (11-12) blocker found in the venom of the
funnel web spider (A. aperta), as shown in Fig.
4A. Despite the low amino acid
sequence homology between tachystatin A and
-aga IVA, tachystatin A
has also been shown to share a remarkable structural similarity with
-aga IVA, as shown in Fig. 4B. In tachystatin A, there
are three
-strands: Phe9-Val12 (strand I),
Thr28-Arg30 (strand II), and
Gly39-Gln42 (strand III). These
-strands
correspond to Gly10-Cys12,
Gly24-Cys27, and
Cys34-Lys37 in
-aga IVA, respectively.
Regarding
-turns, tachystatin A has two
-turns that involve
the residues Leu6-Phe9 (type IV) and
Cys24-Leu27 (type II), whereas in the case of
-aga IVA, there are three
-turns. The first turn in tachystatin A
corresponds to residues 7-10 (type II
-turn) in
-aga IVA, and
the second turn corresponds to residues 20-23 (type IV), although
there is no rigid turn corresponding to the remaining turn of
-aga
IVA (13-16 residues), and this site is as disordered as the N-terminal
region in tachystatin A. The disulfide bonds of
Cys4-Cys24,
Cys11-Cys29, and
Cys23-Cys41 in tachystatin A correspond to
Cys4-Cys20,
Cys12-Cys25, and
Cys19-Cys36 in
-aga IVA, respectively (Fig.
4A), although the disulfide bond
Cys27-Cys34 of
-aga IVA is lacking in
tachystatin A. Three identical disulfides might be a major factor in
the similarity between the solution structures of tachystatin A and
-aga IVA.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
Structure comparisons of tachystatin A
and -aga IVA. A, an amino acid
sequence alignment of tachystatin A and -aga IVA. Consensus amino
acids are represented in small boldface
letters, and the conserved cysteines are indicated in
large boldface letters.
Lines show the identical pattern of disulfide bonds in
tachystatin A and -aga IVA. B, structure comparison of
tachystatin A and -aga IVA. The antiparallel -sheet with a
topology of +2x, 1 is identified in both molecules.
Disulfide bonds are shown by ball-stick models. The
essential residues for chitin binding, Phe9 in tachystatin
A and Tyr9 in -aga IVA, are also shown by a
ball-stick model. The lowest energy molecule of 20 converged
structures was used for tachystatin A, and the -aga IVA
energy-minimized structure was extracted from the Brookhaven Protein
Data Bank, entry code 1OAV (29). These images were generated
by the program MOLMOL (25).
|
|
Kim et al. (30) have reported that the active site of
-aga IVA as a calcium channel blocker is the highly hydrophobic
C-terminal region with no secondary structures. They have also
suggested that the globular structure of the molecule might be
essential for the high affinity binding of calcium channel antagonists
to channel receptor sites. Although tachystatin A has the same
-sheet topology as
-aga IVA, a region corresponding to the active
site as a calcium channel antagonist of
-aga IVA is lacking. A
recent study on calcium channel blocking has clarified that tachystatin A does not have the properties of a calcium channel antagonist (9);
this is a reasonable result in light of the structure-function relationship.
To determine whether
-aga IVA has antimicrobial and chitin-binding
activities, the corresponding experiments were carried out for each
activity. Tachystatin A represents strong antimicrobial activity to a
fungus (P. pastoris) (9). The 50% inhibitory concentration
(IC50) of
-aga IVA for the fungus P. pastoris
was found to be 7.8 µg/ml. Although this value is higher than that of
tachystatin A (0.5 µg/ml) (9), the antifungal activity was represented clearly. In addition, the concentration of
-aga IVA required for 50% binding to chitin was found to be 8.1 µM, which is nearly equivalent to that of tachystatin A
(8.4 µM) (9). These results are summarized in Table
II. These findings suggest that
-aga
IVA and tachystatin A have similar characteristics as
antifungal/chitin-binding peptides and that a
-sheet with a topology
of +2x,
1 may be an essential factor for antifungal/chitin binding activity.
 |
DISCUSSION |
We here determined the three-dimensional structure of the
antimicrobial peptide tachystatin A by means of 1H NMR
measurements and distance geometry-simulated annealing calculations. The structure has an antiparallel triple-stranded
-sheet with a
topology of +2x,
1 as a dominant secondary structure and
three disulfide linkages. Many previous reports of protein structures with this topology have indicated that the folding is a versatile scaffold for molecular stabilization. In the case of antimicrobial substances, the mammalian
- and
-defensins have a triple-stranded
-sheet with +2x,
1 as a common structural feature
(31-33). To our knowledge, the present report is the first to compare
the structural homology of invertebrate and vertebrate antimicrobial peptides. Generally, the high net positive charge of defensins facilitates their electrostatic interaction with polyanionic surfaces of bacterial cells, but their detailed mechanism has not been characterized yet. Because of the structural similarity between tachystatin A and mammalian defensins, it could be considered that
tachystatin A exerts antimicrobial activity in a manner similar to
defensins. Tachystatin A is rich in arginine residues and is thus a
positively charged peptide. All arginines involved in tachystatin A
(Arg3, Arg14, Arg25,
Arg30, Arg40, and Arg43) are
favorably oriented for solvent accessibility. The molecular surface
shown in Fig. 5 indicated that the
regions with positive electrostatic potential are concentrated on one
side of the
-structure regions, with the exception of
Arg14. Contrary to the assembly of charged residues, the
opposite side of the
-structures is occupied by a hydrophobic
surface widely constructed with disordered loops,
Tyr16-Pro22 (loop 1) and
Tyr32-Thr37 (loop 2). This amphiphilic
character is also found in mammalian defensins and may be favorable
when the peptide comes into contact with bacteria and interacts with
their membranes. A positive potential surface may play an important
role in the interaction with the negatively charged membrane, and the
exposed hydrophobic surface may accommodate the binding of tachystatin
A to the membrane.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 5.
Surface of tachystatin A
colored according to the electrostatic potential.
On the -sheet surface (left), the area with positive
potential (blue) distributes widely, whereas the neutral
potential area occupies the opposite surface (right),
where the hydrophobic loop
(Ser15-Ile21) is exposed to the solvent.
The positively charged residues are labeled. These images
were generated by the program MOLMOL (25).
|
|
To date, many antimicrobial peptides have been found in invertebrates,
and these can be classified into three categories on the basis of their
structures: (a) linear or
-helical peptides without
disulfide bonds, (b) peptides with a high content of one or
two kinds of amino acids, and (c) cysteine-rich peptides
(34). Cysteines are rich in the antimicrobial peptides found in the Japanese horseshoe crab, including tachystatin A, and these peptides can be classified as cysteine-rich antimicrobial peptides (2). Noticeable structural motifs of cysteine-rich antimicrobial peptides isolated from invertebrates include the hairpin-like
-sheet motif and the cysteine-stabilized
-
motif (35). Although tachystatin A
belongs to the family of cysteine-rich peptides of invertebrate antimicrobial substances, no structural homology with tachystatin A has
been identified in the cysteine-rich peptide family. Whereas few
structural homologies have been identified between tachystatin A and
other invertebrate antimicrobial peptides, it has been revealed that
tachystatin A shows a significant structural similarity to
-aga IVA,
a calcium channel blocker found in the venom of the funnel web spider
(9). Surprisingly, our results showed that
-aga IVA also has the
antifungal activity, although it was weaker than that of tachystatin A
(Table II). Because
-aga IVA does not form a clear amphiphilic
conformation, its antifungal activity might appear to be weaker than
that of tachystatin A.
The horseshoe crab is a close relative of spiders in evolutionary
history. Thus, both tachystatin A and
-aga IVA are considered to
have evolved from the common ancestor of ancient arthropods as
antimicrobial substances. It is assumed that
-aga IVA is a more
developed molecule than tachystatin A because
-aga IVA affects the
nervous system but tachystatin A does not, and it is thought that the
ancestral antimicrobial peptide added the activity of the calcium
channel antagonist to its function. In contrast, it could be considered
that tachystatin A did not need to develop such a function because of
its life circumstances, given that the horseshoe crab has not developed
for a long time. It is thus considered that tachystatin A has conserved
the original features of the antimicrobial peptide.
Tachystatin A has the chitin-binding property, which has also been
observed in other proteins in small granules of T. tridentatus hemocytes. This study suggests that the molecular
folding observed in tachystatin A marks it as belonging to a newly
identified structural family of antimicrobial and chitin-binding
peptides, because the structure of tachystatin A shows no structural
homology with the known chitin-binding motif. As a characteristic motif
of the peptides with both chitin-binding and antimicrobial activities,
the hevein domain (36, 37) is widely known. Hevein (38) is a
chitin-binding/antimicrobial peptide isolated from rubber tree
(Hevea brasiliensis) latex, and its chitin-binding domain
includes a cysteine-stabilized antiparallel
-sheet and a helical
turn. Although it has been proposed that this domain is involved in
plant peptides, it has also been reported that some invertebrate
chitinases involve this domain and conserve its structural motif
(39-43). Recently, in the first report on the three-dimensional
structure of an invertebrate chitin-binding short peptide (73 residues), Suetake et al. (14) determined the
three-dimensional structure of tachycitin (6), which is an
antimicrobial peptide with the chitin-binding property found in the
hemocytes of the Japanese horseshoe crab. Tachycitin contains the
hevein domain as a chitin-binding domain. Although tachystatin A and
tachycitin are derived from the same source, no structural similarities
have been found between them. The chitin affinity and antifungal
activity of tachystatin A are stronger than those of tachycitin,
although tachystatin A does not have the hevein domain. Thus, the
structural motif of tachystatin A may be more favorable for the chitin
binding and antifungal activity than those of the hevein domain.
Furthermore,
-aga IVA with a structural feature common to
tachystatin A also shows an equivalent level of chitin-binding
activity. Based on the results of the chitin-binding assay of
tachystatin A and
-aga IVA (Table II), both peptides are presumed to
have a similar manner of binding to chitin.
There have been numerous reports that the exposed side chain of the
aromatic residue plays an important role in the recognition of
polysaccharides. Because only two aromatic residues are contained in
-aga IVA, we can select the aromatic residues from both peptides, Tyr9 and Trp14 of
-aga IVA and the
corresponding Phe9 and Tyr16 of tachystatin A,
as essential factors for the recognition of chitin, based on a
comparison of the three-dimensional structures of tachystatin A and
-aga IVA. Phe9 of tachystatin A and Tyr9 of
-aga IVA are located on the
-turn, and Tyr16 of
tachystatin A and Trp14 of
-aga IVA are located on the
disordered loop region. In the case of the cellulose- and xylan-binding
proteins, including the modular structure known as the
carbohydrate-binding module, the aromatic ring of tryptophan on the
-turn plays a key role in the hydrophobic interaction with the
nonpolar face of a sugar ring (44-46). Furthermore, a previous study
on the carbohydrate-binding module demonstrated that tryptophan
residues form a planar surface ideally placed to interact with the flat
surface of cellulose (47). In this study, the structures of tachystatin
A and
-aga IVA showed clearly that the side chains of
Phe9 of tachystatin A and Tyr9 of
-aga IVA
form a planar surface (Fig. 4B). In addition, chitin polymer
has a flat surface like that of cellulose. If tachystatin A and
-aga
IVA recognize chitin in a manner similar to that by which the
carbohydrate-binding module recognizes carbohydrates, then
Phe9 of tachystatin A and Tyr9 of
-aga IVA
would be essential residues for the binding to chitin.
Tachystatin A cannot bind to chitin oligomer but binds to chitin
polymer, suggesting that an additional amino acid may be needed for
strong binding to chitin. Although the aromatic residues in the
disordered region Tyr16 of tachystatin A and
Trp14 of
-aga IVA could not be ruled out as being
related to the binding of chitin in this study, these residues might
also be important for the chitin-binding property. In the future, the
chitin-binding mechanism of tachystatin A will be revealed in detail by
experiments using the mutants altered from Phe9 and
Tyr16 to nonaromatic residues. The causation between the
antimicrobial and chitin binding activities of the newly identified
antimicrobial/chitin-binding structure observed in tachystatin A will
also be clarified.
 |
FOOTNOTES |
*
This work was supported in part by the Center of Excellence
Research Program of the Science and Technology Agency and
grants-in-aid for scientific research from the Ministry of
Education, Science, and Culture of Japan (10680625); by a grant from
the Integrated Research Program for the Development of Insect
Technology of the Ministry of Agriculture, Forestries, and Fisheries of
Japan; and by the Program for Promotion of Basic Research Activities
for Innovative Biosciences (Japan).
The assignment data have been deposited in the BioMagResBank
(BMRB), a National Institutes of Health-funded bioinformatics resource
(Department of Biochemistry, University of Wisconsin, Madison, WI;
www.bmrb.wisc.edu) under accession code 5268.
**
To whom correspondence should be addressed: Division of
Biological Sciences, Graduate School of Science, Hokkaido
University, Sapporo 060-0810, Japan. Tel.: 81-11-706-2773; Fax:
81-11-706-2771; E-mail:
nitta@sci.hokudai.ac.jp.
Published, JBC Papers in Press, April 16, 2002, DOI 10.1074/jbc.M111120200
 |
ABBREVIATIONS |
The abbreviations used are:
-aga IVA,
-agatoxin IVA;
r.m.s., root mean square;
NOE, nuclear Overhauser
effect;
NOESY, NOE spectroscopy;
DQF-COSY, double quantum-filtered
correlation spectroscopy;
TOCSY, total correlation spectroscopy;
E.
COSY, exclusive correlation spectroscopy;
DANTE, delays alternating
with nutation for tailored excitation.
 |
REFERENCES |
| 1.
|
Hoffmän, J. A.,
Reichhart, J. M.,
and Hetru, C.
(1996)
Curr. Opin. Immunol.
8,
8-13[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Iwanaga, S.,
Kawabata, S.,
and Muta, T.
(1998)
J. Biochem. (Tokyo)
123,
1-15[Abstract/Free Full Text]
|
| 3.
|
Söderhall, K.,
and Cerenius, L.
(1998)
Curr. Opin. Immunol.
10,
23-28[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Nakamura, T.,
Furunaka, H.,
Miyata, T.,
Tokunaga, F.,
Muta, T.,
Iwanaga, S.,
Niwa, M.,
Takao, T.,
and Shimonishi, Y.
(1988)
J. Biol. Chem.
263,
16709-16713[Abstract/Free Full Text]
|
| 5.
|
Saito, T.,
Kawabata, S.,
Shigenaga, T.,
Takayenoki, Y.,
Cho, J.,
Nakajima, H.,
Hirata, M.,
and Iwanaga, S.
(1995)
J. Biochem. (Tokyo)
117,
1131-1137[Abstract/Free Full Text]
|
| 6.
|
Kawabata, S.,
Nagayama, R.,
Hirata, M.,
Shigenaga, T.,
Agarwala, K. L.,
Saito, T.,
Cho, J.,
Nakajima, H.,
Takagi, T.,
and Iwanaga, S.
(1996)
J. Biochem. (Tokyo)
120,
1253-1260[Abstract/Free Full Text]
|
| 7.
|
Toh, Y.,
Mizutani, A.,
Tokunaga, F.,
Muta, T.,
and Iwanaga, S.
(1991)
Cell Tissue Res.
266,
137-147[CrossRef]
|
| 8.
|
Kawabata, S.,
Muta, T.,
and Iwanaga, S.
(1996)
in
New Directions in Invertebrate Immunology
(Söderhäll, K.
, Iwanaga, S.
, and Vasta, G. R., eds)
, pp. 255-284, SOS Publications, Fair Haven, NJ
|
| 9.
|
Osaki, T.,
Omotezako, M.,
Nagayama, R.,
Hirata, M.,
Iwanaga, S.,
Kasahara, J.,
Hattori, J.,
Sugiyama, H.,
and Kawabata, S.
(1999)
J. Biol. Chem.
274,
26172-26178[Abstract/Free Full Text]
|
| 10.
|
Mintz, I. M.,
Venema, V. J.,
Swiderek, K. M.,
Lee, T. D.,
Bean, B. P.,
and Adams, M. E.
(1992)
Nature
355,
827-829[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Regan, L. J.
(1991)
J. Neurosci.
11,
2259-2269[Abstract]
|
| 12.
|
Uchitel, O. D.,
Protti, D. A.,
Sanchez, V.,
Cherksey, B. D.,
Sugimori, M.,
and Llinas, R.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
3330-3333[Abstract/Free Full Text]
|
| 13.
|
Kawano, K.,
Yoneya, T.,
Miyata, T.,
Yoshikawa, K.,
Tokunaga, F.,
Terada, Y.,
and Iwanaga, S.
(1990)
J. Biol. Chem.
265,
15365-15367[Abstract/Free Full Text]
|
| 14.
|
Suetake, T.,
Tsuda, S.,
Kawabata, S.,
Miura, K.,
Iwanaga, S.,
Hikichi, K.,
Nitta, K.,
and Kawano, K.
(2000)
J. Biol. Chem.
275,
17929-17932[Abstract/Free Full Text]
|
| 15.
|
Rance, M.,
Sørensen, O. W.,
Bodenhausen, G.,
Wagner, G.,
Ernst, R. R.,
and Wüthrich, K.
(1983)
Biochem. Biophys. Res. Commun.
117,
479-485[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Braunschweiler, L.,
and Ernst, R. R.
(1983)
J. Magn. Reson.
53,
521-528
|
| 17.
|
Bax, A.,
and Davis, D. G.
(1985)
J. Magn. Reson.
65,
355-360
|
| 18.
|
Jeener, J.,
Meier, B. N.,
Bachmann, P.,
and Ernst, R. R.
(1979)
J. Chem. Phys.
71,
4546-4553[CrossRef]
|
| 19.
|
Griesinger, C.,
Sørensen, O. W.,
and Ernst, R. R.
(1985)
J. Am. Chem. Soc.
107,
6394-6396
|
| 20.
|
Zuiderweg, E. P. R.,
Hallenga, K.,
and Olejniczak, E. T.
(1986)
J. Magn. Reson.
70,
336-343
|
| 21.
|
Delaglio, F.,
Grzesiek, S.,
Vuister, G.,
Zhu, G.,
Pfeifer, J.,
and Bax, A.
(1995)
J. Biomol. NMR
6,
277-293[Medline]
[Order article via Infotrieve]
|
| 22.
|
Bartels, C.,
Xia, T. H.,
Billeter, M.,
Güntert, P.,
and Wüthrich, K.
(1995)
J. Biomol. NMR
5,
1-10[Medline]
[Order article via Infotrieve]
|
| 23.
|
Brünger, A. T.
(1993)
X-PLOR Manual, Version 3.1
, Yale University, New Haven, CT
|
| 24.
|
Clore, G. M.,
Gronenborn, A. M.,
Nilges, M.,
and Ryan, C. A.
(1987)
Biochemistry
26,
8012-8023[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Koradi, R.,
Billeter, M.,
and Wüthrich, K.
(1996)
J. Mol. Graph.
14,
51-55[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Wüthrich, K.
(1986)
NMR of Proteins and Nucleic Acids
, John Wiley & Sons, Inc., New York
|
| 27.
|
Hyberts, S. G.,
Märki, W.,
and Wagner, G.
(1987)
Eur. J. Biochem.
164,
625-635[Medline]
[Order article via Infotrieve]
|
| 28.
|
Lewis, P. N.,
Momany, F. A.,
and Scheraga, H. A.
(1973)
Biochim. Biophys. Acta
303,
211-229[Medline]
[Order article via Infotrieve]
|
| 29.
|
Wilmot, C. M.,
and Thornton, J. M.
(1990)
Protein Eng.
3,
479-493[Abstract/Free Full Text]
|
| 30.
|
Kim, J. I.,
Konishi, S.,
Iwai, H.,
Kohno, T.,
Gouda, H.,
Shimada, I.,
Sato, K.,
and Arata, Y.
(1995)
J. Mol. Biol.
250,
659-671[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Selsted, M. E.,
Tang, Y.,
Morris, W. J.,
McGuire, P. A.,
Novotny, M. J.,
Smith, W.,
Henschen, A. H.,
and Cullor, J. S.
(1993)
J. Biol. Chem.
268,
6641-6648[Abstract/Free Full Text]
|
| 32.
|
Tang, Y.,
and Selsted, M. E.
(1993)
J. Biol. Chem.
268,
6649-6653[Abstract/Free Full Text]
|
| 33.
|
Zimmermann, G. R.,
Legault, P.,
Selsted, M. E.,
and Pardi, A.
(1995)
Biochemistry
34,
13663-13671[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Dimarcq, J.,
Bulet, P.,
Hetru, C.,
and Hoffmann, J.
(1998)
Biopolymers
47,
465-477[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Cornet, B.,
Bonmatin, J.,
Hetru, C.,
Hoffmann, J. A.,
Ptak, M.,
and Vovelle, F.
(1995)
Structure
3,
435-448[Medline]
[Order article via Infotrieve]
|
| 36.
|
Beintema, J. J.
(1994)
FEBS Lett.
350,
159-163[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Anderson, N. H.,
Cao, B.,
Rodríguez-Romero, A.,
and Arreguin, B.
(1993)
Biochemistry
32,
1407-1422[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Jekel, P. A.,
Hartmann, B. H.,
and Beintema, J. J.
(1991)
Eur. J. Biochem.
200,
123-130[Medline]
[Order article via Infotrieve]
|
| 39.
|
Krishnan, A.,
Nair, P. N.,
and Jones, D.
(1994)
J. Biol. Chem.
269,
20971-20976[Abstract/Free Full Text]
|
| 40.
|
Watanabe, T.,
Kono, M.,
Aida, K.,
and Nagasawa, H.
(1996)
Mol. Mar. Biotechnol.
5,
299-303
|
| 41.
|
Shen, Z.,
and Jacobs-Lorena, M.
(1997)
J. Biol. Chem.
272,
28895-28900[Abstract/Free Full Text]
|
| 42.
|
Elvin, C. M.,
Vuocolo, T.,
Pearson, R. D.,
East, I. J.,
Riding, G. A.,
Eisemann, C. H.,
and Tellam, R. L.
(1996)
J. Biol. Chem.
271,
8925-8935[Abstract/Free Full Text]
|
| 43.
|
Wang, P.,
and Granados, R. R.
(1997)
J. Biol. Chem.
272,
16663-16669[Abstract/Free Full Text]
|
| 44.
|
Tormo, J.,
Lamed, R.,
Chirino, A. J.,
Morag, E.,
Bayer, E. A.,
Shoham, Y.,
and Steitz, T. A.
(1996)
EMBO J.
15,
5739-5751[Medline]
[Order article via Infotrieve]
|
| 45.
|
Din, N.,
Forsythe, I. J.,
Burntnick, L. D.,
Gilkes, N. R.,
Miller, R. C., Jr.,
Warren, R. A.,
and Kilburn, D. G.
(1994)
Mol. Microbiol.
11,
747-755[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Nagy, T.,
Simpson, P. J.,
Williamson, M. P.,
Hazlewood, G. P.,
Gilbert, H. J.,
and Orosz, T. A.
(1998)
FEBS Lett.
429,
312-316[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Simpson, P. J.,
Xie, H.,
Bolam, D. N.,
Gilbert, H. J.,
and Williamson, M. P.
(2000)
J. Biol. Chem.
275,
41137-41142[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.